Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Curran

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Nature Communications|November 14, 2017
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brainManisha Singh, Christina Vianden, Mark J Cantwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma ModelsAria Sabbagh, Kevin Beccaria, Xiaoyang Ling, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
ISA101 and nivolumab for HPV-16<sup>+</sup> cancer: updated clinical efficacy and immune correlates of responseLuana Guimaraes de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Oncology|October 20, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular CarcinomaMichael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, et al.
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
The Journal of Clinical Investigation|February 16, 2026
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma modelShashwat Tripathi, Hinda Najem, Lisa Hurley, et al.
JCI Insight|July 30, 2020
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restorationMartina Ott, Karl-Heinz Tomaszowski, Anantha Marisetty, et al.
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Nature Communications|November 14, 2017
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brainManisha Singh, Christina Vianden, Mark J Cantwell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2021
Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma ModelsAria Sabbagh, Kevin Beccaria, Xiaoyang Ling, et al.
Journal for Immunotherapy of Cancer|February 23, 2022
ISA101 and nivolumab for HPV-16<sup>+</sup> cancer: updated clinical efficacy and immune correlates of responseLuana Guimaraes de Sousa, Kimal Rajapakshe, Jaime Rodriguez Canales, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T CellsChad Tang, James W Welsh, Patricia de Groot, et al.
Oncology|October 20, 2024
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular CarcinomaMichael LaPelusa, Shadi Chamseddine, Hop Sanderson Tran Cao, et al.
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
The Journal of Clinical Investigation|February 16, 2026
STING-induced blood-brain barrier opening combined with radiotherapy potentiates antitumor response in a high-grade glioma modelShashwat Tripathi, Hinda Najem, Lisa Hurley, et al.
JCI Insight|July 30, 2020
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restorationMartina Ott, Karl-Heinz Tomaszowski, Anantha Marisetty, et al.
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
Pageof 9